Global Consensus Renames PCOS to Polyendocrine Metabolic Ovarian Syndrome (PMOS)

For nearly a century, the label polycystic ovary syndrome (PCOS) has caused significant distress and clinical confusion for millions of individuals. Originally described in 1935, the term focused almost exclusively on the morphological appearance of ovaries during surgical inspection or pelvic ultrasound.

That diagnostic focus was fundamentally flawed. The fluid-filled structures visible on an ultrasound are not pathological ovarian cysts that rupture or require surgical excision. They are normal antral follicles that have paused their maturation process because of hormonal signaling disruptions.

Furthermore, up to 25% of individuals with regular menstrual cycles and normal androgen levels demonstrate multifollicular ovarian morphology on ultrasound, while many patients experiencing profound metabolic dysfunction present with completely unremarkable pelvic imaging. The historical name obscured the underlying condition while anchoring patient anxiety to the wrong organ.

The updated terminology, Polyendocrine Metabolic Ovarian Syndrome (PMOS), reflects modern endocrine science. The syndrome is not an isolated gynecological disorder, but a multi-organ endocrine and metabolic condition with deep roots in cellular glucose handling and neuroendocrine feedback loops.

The primary physiological driver in the vast majority of patients is intrinsic insulin resistance, which exists independently of body mass index. Compensatory hyperinsulinemia stimulates the ovarian theca cells to overproduce androgens such as testosterone and androstenedione. Concurrently, higher circulating insulin suppresses hepatic sex hormone-binding globulin (SHBG) production, substantially increasing the concentration of biologically active, circulating free testosterone.

These hormonal imbalances disrupt the pulsatile release of gonadotropin-releasing hormone (GnRH) and luteinizing hormone (LH), impairing follicle selection and regular ovulation. Beyond reproductive consequences, chronic hyperinsulinemia and low-grade systemic inflammation generate long-term cardiovascular risks, dyslipidemia, endothelial stiffness, and hepatic steatosis.

For more than two decades, clinicians relied on the 2003 Rotterdam criteria, which required meeting any two of three features: irregular or absent ovulation, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology on ultrasound. In practice, this framework frequently allowed providers to confirm a diagnosis based purely on irregular cycles and an ultrasound, without ever ordering metabolic blood panels.

The PMOS consensus framework mandates a comprehensive baseline metabolic assessment. Clinicians are guided to evaluate fasting insulin, homeostatic model assessment of insulin resistance (HOMA-IR), lipid subfractions, 2-hour oral glucose tolerance testing with paired insulin measurements, and liver enzyme panels alongside total testosterone, free testosterone, and DHEA-sulfate.

This shift ensures that cardiovascular and metabolic risks are identified and treated in a patient's early twenties and thirties, rather than remaining unaddressed until a patient presents with prediabetes, gestational diabetes, or hypertension years later.

Standard gynecological encounters for PMOS often last only ten to fifteen minutes, concluding with a prescription for combined oral contraceptive pills to force a scheduled withdrawal bleed. While hormonal contraception can protect the endometrium from hyperplasia, it does not treat underlying insulin resistance or metabolic dysregulation.

Certified Nurse-Midwives (CNMs) approach PMOS with a whole-person, trauma-informed philosophy. In Arizona, CNMs are licensed Advanced Practice Registered Nurses (APRNs) with independent diagnostic and prescriptive authority across Schedule II through V medications. Midwives provide comprehensive gynecological and well-woman primary care across the lifespan.

During extended appointments, midwives examine the intersections of sleep architecture, chronic high cortisol, nutritional timing, and physical movement on insulin sensitivity. Midwives prescribe evidence-based pharmacotherapies, such as metformin or targeted cycle-regulating therapies, evaluate evidence-backed supplements like myo-inositol and d-chiro-inositol, and collaborate closely with endocrinologists and reproductive specialists when advanced co-management is warranted.

Patients diagnosed with PMOS are frequently told prematurely that they will struggle with permanent infertility. This fatalistic messaging causes unnecessary psychological trauma. The difficulty in PMOS is anovulation, not a depletion of viable oocytes.

When underlying insulin resistance and androgen excess are managed, ovulatory function often resumes spontaneously. Midwives support patients with basal body temperature charting, cervical mucus tracking, and luteal phase progesterone testing to confirm ovulation.

For individuals planning a pregnancy, early optimization of glucose metabolism reduces the incidence of early pregnancy loss, gestational diabetes mellitus, and preeclampsia. By reframing the condition as PMOS, patients and clinicians can partner on sustainable metabolic health long before conception takes place.